PCM
IRON icon

Penserra Capital Management’s Disc Medicine IRON Stock Holding History

Penserra Capital Management’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-379
Closed -$19K – 1083
2022
Q2 		$19K Buy
379
+47
+14% +$2.08K ﹤0.01% 1117
2022
Q1 		$13K Buy
332
+49
+17% +$2.57K ﹤0.01% 1367
2021
Q4 		$24K Sell
283
-19
-6% -$1.86K ﹤0.01% 1212
2021
Q3 		$36K Buy
302
+83
+38% +$11.3K ﹤0.01% 1143
2021
Q2 		$42K Sell
219
-222
-50% -$73K ﹤0.01% 1039
2021
Q1 		$179K Buy
+441
New +$197K ﹤0.01% 602

Other funds holding IRON

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
FCOMV
Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Penserra Capital Management's IRON Position: Q3 2022 in Review

Penserra Capital Management sold out of Disc Medicine (IRON) in Q3 2022, closing a stake of 379 shares — an estimated $19K sold.

Penserra Capital Management first reported a position in IRON in Q1 2021 and held it in 6 quarters. The position peaked at $179K in Q1 2021. 44 funds tracked by Wall St. Rank hold IRON as of Q3 2022.

  • Penserra Capital Management reported no remaining Disc Medicine position as of Q3 2022 after selling out during the quarter.
  • Penserra Capital Management sold 379 Disc Medicine shares in Q3 2022, an estimated $19K.
  • Penserra Capital Management first reported a position in Disc Medicine in Q1 2021 and held it in 6 quarters.
  • Penserra Capital Management's Disc Medicine position peaked at $179K in Q1 2021.
  • 44 funds tracked by Wall St. Rank held Disc Medicine as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.